Daflon is an oral micronized purified phlebotonic flavonoid fraction containing 90% diosmin and 10% hesperidin. It is manufactured by Laboratoires Servier and often used to treat or manage disorders of the blood vessels.[1][2] Flavonoids are a type of phytochemical that have been associated with various effects on human health and are a component of many different pharmaceutical, nutraceutical, and cosmetic preparations.[3] Diosmin is a flavone glycoside that is derived from hesperidin. Hesperidin is a flavone that is extracted from citrus fruits.[4]
Vein diseases and hemorrhoids edit
Daflon is not an FDA-approved medication, and therefore it cannot be advertised for treatment of diseases in the United States. Daflon is under preliminary research for its potential use in treating vein diseases,[5] or hemorrhoids.[6] It is sold as a drug in France,[7][8] Spain,[9] Malaysia[10][11] and Belgium.
There is moderate certainty evidence for the effectiveness of daflon for slightly reducing oedema compared to placebo in the treatment of chronic venous insufficiency.[12] Little to no differences in quality of life after treatment with Daflon were found and there is low certainty evidence that this class of drugs do not influence ulcer healing.[12] Diosmiplex, a micronized purified flavonoid fraction of daflon, with similar venous insufficiency indication, is sold as a prescription medical food in the US.[13]
Pharmacological activity edit
Daflon plays a crucial role in the prevention of perivascular edema formation and treatment of venous stasis. This activity can be explained by its antagonist activity against prostaglandin E2 (PgE2) and thromboxane (TxA2) biosynthesis leading to inhibition of inflammatory process. Moreover, it also has a contraction activity on the lymphatic vessels which cause the lymphatic flow maximal.[14]
Dosage edit
For venous insufficiency, the dosage is 2 tablets of 500mg daily. For acute hemorrhoidal attack, the dosage is 6 tablets daily for 4 days, followed by 4 tablets daily over the next 3 days.[15] For chronic venous disease, the dosage is 2 tablets a day for at least 2 months.[16]
Side effects edit
Possible side effects include routine gastric disorders and neurovegetative disorders, however, toxicology studies indicate that diosmin is quite safe.[2] Diosmin interacts in an inhibitory manner with some metabolic enzymes so drug-interactions are probable.[2]
References edit
- ^ "Offocial Monograph. Daflon 500: Summary of Product Characteristics" (PDF). www.servier.com.ve. Archived (PDF) from the original on 2016-12-28. Retrieved 2018-12-09.
- ^ a b c Gerges, Samar H.; Wahdan, Sara A.; Elsherbiny, Doaa A.; El-Demerdash, Ebtehal (2021-10-23). "Pharmacology of Diosmin, a Citrus Flavone Glycoside: An Updated Review". European Journal of Drug Metabolism and Pharmacokinetics. 47 (1): 1–18. doi:10.1007/s13318-021-00731-y. ISSN 2107-0180. PMID 34687440. S2CID 239473375.
- ^ Panche, A. N.; Diwan, A. D.; Chandra, S. R. (2016). "Flavonoids: an overview". Journal of Nutritional Science. 5: e47. doi:10.1017/jns.2016.41. ISSN 2048-6790. PMC 5465813. PMID 28620474.
- ^ Gerges, Samar H.; Wahdan, Sara A.; Elsherbiny, Doaa A.; El-Demerdash, Ebtehal (2021-10-23). "Pharmacology of Diosmin, a Citrus Flavone Glycoside: An Updated Review". European Journal of Drug Metabolism and Pharmacokinetics. 47 (1): 1–18. doi:10.1007/s13318-021-00731-y. ISSN 2107-0180. PMID 34687440. S2CID 239473375.
- ^ Lyseng-Williamson KA, Perry CM (2003). "Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids". Drugs. 63 (1): 71–100. doi:10.2165/00003495-200363010-00005. PMID 12487623. S2CID 46982572.
- ^ Perera, Nirmal; Liolitsa, Danae; Iype, Satheesh; Croxford, Anna; Yassin, Muhammed; Lang, Peter; Ukaegbu, Obioha; van Issum, Christopher (15 August 2012). "Phlebotonics for haemorrhoids". Cochrane Database of Systematic Reviews (8): CD004322. doi:10.1002/14651858.cd004322.pub3. ISSN 1465-1858. PMID 22895941. S2CID 28445593.
- ^ "Daflon - EurekaSanté par Vidal". EurekaSanté (in French). Retrieved 2018-02-17.
- ^ "Notice patient - Daflon 500 mg, comprimé pelliculé - Base de données publique des médicaments". base-donnees-publique.medicaments.gouv.fr (in French). Retrieved 2018-02-17.
- ^ Spanish medicines agency (in Spanish)
- ^ "Drug Formulary" (PDF). Hospital Tengku Ampuan Rahimah. 2011. Archived (PDF) from the original on 2017-05-17.
- ^ Norliza (2011-09-14). "Kehamilan & Perubatan". Portal MyHealth (in Malay). Retrieved 2020-01-17.
- ^ a b Martinez-Zapata, Maria José; Vernooij, Robin Wm; Simancas-Racines, Daniel; Uriona Tuma, Sonia Maria; Stein, Airton T.; Moreno Carriles, Rosa Maria M.; Vargas, Emilio; Bonfill Cosp, Xavier (November 3, 2020). "Phlebotonics for venous insufficiency". The Cochrane Database of Systematic Reviews. 2020 (11): CD003229. doi:10.1002/14651858.CD003229.pub4. ISSN 1469-493X. PMC 8094625. PMID 33141449.
- ^ Bush, Ronald; Comerota, Anthony; Meissner, Mark; Raffetto, Joseph D.; Hahn, Steven R.; Freeman, Katherine (April 2017). "Recommendations for the medical management of chronic venous disease: The role of Micronized Purified Flavanoid Fraction (MPFF)". Phlebology. 32 (1_suppl): 3–19. doi:10.1177/0268355517692221. ISSN 1758-1125. PMID 28211296. S2CID 24389276.
- ^ Labrid, C. (June 1994). "Pharmacologic properties of Daflon 500 mg". Angiology. 45 (6 Pt 2): 524–530. ISSN 0003-3197. PMID 8203782.
- ^ "Diosmin Uses, Benefits & Dosage - Drugs.com Herbal Database". Drugs.com. Retrieved 2020-01-17.
- ^ Publishing, Licorn (2009-11-26). "Benefit of Daflon 500 mg in chronic venous disease-related symptoms". Servier - Phlebolymphology. Retrieved 2020-01-17.